
    
      This is a prospective, open, single-center, randomized controlled trial. Number of patients:
      240 patients will be included and undertaken TEVAR.About 120 patients will be given
      glucocorticoid within 2h after TEVAR as experimental group, and the other 120 patients will
      be given saline as control group.

      Follow-up: 1. aortic computed tomographic angiography (CTA) examination 6, 12 and 24 months
      after TEVAR; 2. telephone or clinical follow-up at 1, 2, 3, 6, 12 and 24 months.

      Primary outcome measure: aorta-related adverse events. Second outcome measure: 30-day
      mortality after TEVAR, success rate of endovascular repair, drug-related adverse events.
    
  